Processa (PCSA) CEO George Ng Exercises Options — 1,600 Shares

What Happened

• George K. Ng, Chief Executive Officer of Processa Pharmaceuticals (PCSA), reported exercising or converting derivatives (transaction code M) to acquire 1,600 shares on August 8, 2026. The filing also shows a simultaneous reported disposition of 1,600 shares at $0.00 (no cash proceeds reported).
• The filing includes footnotes indicating the shares relate to a distribution of a time‑based service award and to an option vesting schedule. No open‑market sale or cash proceeds are shown, so this is not a typical sale to raise money.

Key Details

• Transaction date: August 8, 2026; Form 4 filed August 11, 2026 (filed within typical SEC two-business-day window following the transaction).
• Reported entries: Acquired 1,600 shares (M = exercise/conversion of derivative); Disposed 1,600 shares at $0.00.
• Shares owned after the transaction: not specified in the provided filing details.
• Footnotes: F1 = distribution of time‑based service award; F2 = option vesting schedule (1/3 on first anniversary, remainder over two years); F3 = reflects 1-for-25 reverse split effective Dec 17, 2025.
• Transaction code meaning: M = exercise or conversion of derivative security.

Context

• This was not an open‑market sale or purchase; the entries reflect an option/derivative exercise or award distribution and a corresponding $0 disposal entry. Such filings can reflect internal conversions, award distributions, tax withholdings, or transfers rather than market sentiment-driven buying or selling.
• Because no cash was received and the filing ties to service awards/vesting, this should be viewed as an administrative/compensation event rather than a straightforward insider investment or liquidation.